[CAS NO. 2057509-72-3] AZD4573
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [2057509-72-3]
Catalog
SLK-S8719
Brand
Selleck
CAS
2057509-72-3
DESCRIPTION [2057509-72-3]
Overview
| MDL | MFCD31657407 |
|---|---|
| Molecular Weight | 429.94 |
| Molecular Formula | C22H28ClN5O2 |
| SMILES | O=C([C@@H]1C[C@H](NC(C)=O)CCC1)NC2=NC=C(Cl)C(C3=C(CC(C)(C)C4)N4N=C3)=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3259 mL | 11.6295 mL | 23.2591 mL |
| 5 mM | 0.4652 mL | 2.3259 mL | 4.6518 mL |
| 10 mM | 0.2326 mL | 1.1630 mL | 2.3259 mL |
| 50 mM | 0.0465 mL | 0.2326 mL | 0.4652 mL |
Description
AZD4573 is a potent inhibitor of (IC50 of <0.004 μM) with fast-off binding kinetics (t = 16 min) and high selectivity versus other kinases, including other CDK family kinases.
Targets
| CDK9 [1] |
| <0.004 μM |
In vitro
Short-term treatment with AZD4573 leads to a rapid dose- and time-dependent decrease in cellular pSer2-RNAPII, resulting in activation of caspase 3 and cell apoptosis in a broad range of haematological cancer cell lines (e.g. caspase activation EC50 0.0137 μM in an acute myeloid leukemia model MV4-11).In human cancer cell line panel screens, AZD4573 demonstrates the ability to induce rapid caspase activation (6h) and loss of viability (24h) across a diverse set of hematological cancers (median caspase EC50 = 30 nM, GI50 = 11 nM) but with minimal effect on solid tumors (median EC50 & GI50 >30 μM).
References
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.